Tyvaso Revenue Fuels United Therapeutics Amid Phase 3 Trial Milestones and Bioengineering Expansion

Introduction

UNITED THERAPEUTICS CORP (NASDAQ: UTHR) is an American biotechnology company organized as a public benefit corporation. Founded in 1996, the firm develops pharmaceuticals for rare, life-threatening cardiopulmonary diseases and advances organ manufacturing technologies. As of December 4, 2025, UTHR shares closed at $461.11, a decrease of 4.13% on NASDAQ, with a trading volume of 122,290 shares (average daily volume: 139).

Corporate Structure

Headquartered in Silver Spring, Maryland, and Research Triangle Park, North Carolina, United Therapeutics employs between 1,001 and 5,000 people across its global sites. The company maintains six FDA-approved therapies treating pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD), and high-risk pediatric neuroblastoma. Its public benefit charter formalizes a dual mission: delivering shareholder value while working to expand access to transplantable organs through xenotransplantation, regenerative medicine, and ex-vivo organ perfusion.

Biotechnology by Louis Reed

Recent Developments and News

• On September 2, 2025, UTHR filed a Form 8-K (items 8.01 and 9.01), providing corporate governance updates.
• On October 29, 2025, the company filed both an 8-K (items 2.02 and 9.01) and its quarterly report on Form 10-Q for the period ended September 30, 2025.
• In June 2025, United Therapeutics was named to Fortune's “100 Best Workplaces for Parents” list for the second consecutive year.
• On November 18, 2025, TIME ranked UTHR 47th on its inaugural America’s Growth Leaders 2026 list, evaluating revenue growth, financial health, and stock performance.

Financial and Strategic Aspects

United Therapeutics reported $1.62 billion in revenue from Tyvaso for the fiscal year 2024, attributed to its treprostinil inhalation platforms (Tyvaso and Tyvaso DPI). The company’s pipeline includes two Phase 3 trials—TETON 1 and TETON 2—evaluating nebulized treprostinil in patients with idiopathic pulmonary fibrosis. In February 2025, TETON 1 reached full enrollment with 598 patients, and an independent data monitoring committee recommended continuation of the trial. In late 2023, United Therapeutics expanded its organ bioengineering capabilities through acquisitions of IVIVA Medical (October 2023) and Miromatrix Medical (December 2023).

Market Position and Industry Context

Within the biotechnology sector, United Therapeutics focuses on therapeutics related to orphan diseases and organ manufacturing. Its emphasis on PAH, PH-ILD, pulmonary fibrosis, and the supply of transplantable organs distinguishes it from competitors that concentrate solely on pharmaceuticals or medical devices. With an estimated 100,000 patients in the U.S. living with idiopathic pulmonary fibrosis and challenges related to organ shortages, UTHR’s integrated drug and bioengineering strategy seeks to address various unmet needs in cardiopulmonary care and transplantation.

TL;DR

Shares at $461.11 (–4.13%) on December 4, 2025; September and October SEC filings reported governance and quarterly results. June 2025: Fortune Workplace accolade; November 2025: TIME Growth Leader (#47). Fiscal 2024 Tyvaso revenue was $1.62 billion. The TETON 1 Phase 3 trial fully enrolled in February 2025, with TETON 2 ongoing. Acquisitions of IVIVA and Miromatrix in 2023 enhance the organ-engineering pipeline, positioning UTHR for potential late-stage data readouts in 2026.